MedDRA preferred term

Wrong technique in device usage process: adverse event reports recording this term

45,123 reports to FDA record it, 2009–2026; 0.2% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

45,123
reports recording the term: 0.2% of all reports; 4,854
reports, 12 months to June 2026: 5,410 in the 12 months before; 9.5%
marked serious by the reporter: 57.4% across all reports; 0.3%
record death among outcomes, as reported: 9.1% across all reports

"Wrong technique in device usage process" is a MedDRA preferred term recorded in 45,123 adverse event reports received by FDA, 0.2% of the database, from June 2009 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

4,854 reports recorded it in the 12 months to June 2026, down 10% from 5,410 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 9.5% are marked serious, 0.3% include death among the outcomes and 3.6% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Genotropin, Trelegy Ellipta and Albuterol sulfate. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Genotropin	—	4,476	9.9%
Trelegy Ellipta	Anticholinergic	3,157	11.8%
Albuterol sulfate	beta2-Adrenergic agonist	2,845	6.4%
Bydureon Bcise	—	2,621	20.3%
Ventolin Hfa	beta2-Adrenergic agonist	2,603	11.5%
Breo Ellipta	Corticosteroid	2,259	10.2%
Anoro Ellipta	Anticholinergic	1,615	12.9%
Benlysta	B lymphocyte stimulator-specific inhibitor	1,543	5.9%
Advair Diskus	Corticosteroid	1,463	7.1%
Nucala	Interleukin-5 antagonist	1,441	4.7%
Symbicort	Corticosteroid	1,368	3.5%
Lantus Solostar	Insulin analog	1,143	2.5%
Breztri	Corticosteroid	1,140	15.9%
Bydureon	—	1,075	5.5%
Tanzeum	—	929	11%
Flovent	Corticosteroid	736	6.8%
Repatha	PCSK9 inhibitor	708	0.5%
Dupixent	Interleukin-4 receptor alpha antagonist	585	0.1%
Cosentyx	Interleukin-17A antagonist	522	0.3%
Incruse Ellipta	Anticholinergic	517	11.3%
Advair Hfa	Corticosteroid	501	2.6%
Arnuity Ellipta	Corticosteroid	450	17.3%
Budesonide Formoterol Glycopyrronium	—	441	9%
Aimovig	—	429	0.8%
Flovent Diskus	—	350	13.1%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.2% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Corticosteroid	9,119	1.1%	0%
Anticholinergic	5,630	3.5%	0%
beta2-Adrenergic agonist	5,589	6.1%	0.7%
Insulin analog	2,018	0.7%	0.1%
B lymphocyte stimulator-specific inhibitor	1,567	5.2%	3.3%
Interleukin-5 antagonist	1,514	3.2%	0.5%
PCSK9 inhibitor	970	0.5%	0.8%
Interleukin-4 receptor alpha antagonist	637	0.1%	0.3%
Interleukin-17A antagonist	573	0.3%	0.1%
Recombinant human growth hormone	530	2.5%	3.1%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.2%101

2 to 114.7%2,110

12 to 174.4%1,988

18 to 444.8%2,186

45 to 6411.4%5,146

65 to 7410.3%4,644

75 and over8.6%3,870

Age not given55.6%25,078

Patient sex

Female57%25,705

Male33.6%15,163

Not given9.4%4,255

Grey bar: all 20,646,523 reports in the database. 92.7% of these reports give the United States as the country.

Questions about "Wrong technique in device usage process"

What does "Wrong technique in device usage process" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record wrong technique in device usage process?

45,123 reports through June 2026 (0.2% of all reports), 4,854 of them in the latest 12 months.

Which drugs appear most often in these reports?

Genotropin (4,476), Trelegy Ellipta (3,157), Albuterol sulfate (2,845), Bydureon Bcise (2,621) and Ventolin Hfa (2,603). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.